Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.

Autor: Melén CM; Department of Medicine at Huddinge, Division of Hematology, Karolinska Institutet, Stockholm, Sweden.; Medical Unit Hematology, Karolinska University Hospital, Stockholm, Sweden., Merrien M; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden., Wasik AM; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden., Panagiotidis G; Department of Laboratory Medicine, Division of Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Unit of Clinical Pharmacology, University Hospital, Stockholm, Sweden., Beck O; Department of Laboratory Medicine, Division of Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Unit of Clinical Pharmacology, University Hospital, Stockholm, Sweden., Sonnevi K; Department of Medicine at Huddinge, Division of Hematology, Karolinska Institutet, Stockholm, Sweden.; Medical Unit Hematology, Karolinska University Hospital, Stockholm, Sweden., Junlén HR; Department of Medicine at Huddinge, Division of Hematology, Karolinska Institutet, Stockholm, Sweden.; Medical Unit Hematology, Karolinska University Hospital, Stockholm, Sweden., Christensson B; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden., Sander B; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden., Wahlin BE; Department of Medicine at Huddinge, Division of Hematology, Karolinska Institutet, Stockholm, Sweden.; Medical Unit Hematology, Karolinska University Hospital, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jun; Vol. 63 (6), pp. 1387-1397. Date of Electronic Publication: 2022 Jan 17.
DOI: 10.1080/10428194.2021.2020776
Abstrakt: This phase II clinical trial investigates a one-time oromucosal dose of tetrahydrocannabinol/cannabidiol (THC/CBD) in 23 patients with indolent leukemic B cell lymphomas. Primary endpoint was a significant reduction in leukemic B cells. Grade 1 - 2 adverse events were seen in 91% of the patients; most common were dry mouth (78%), vertigo (70%), and somnolence (43%). After THC/CBD a significant reduction in leukemic B cells (median, 11%) occurred within two hours ( p =  .014), and remained for 6 h without induction of apoptosis or proliferation. Normal B cells and T cells were also reduced. CXCR4 expression increased on leukemic cells and T cells. All effects were gone by 24 h. Our results show that a single dose of THC/CBD affects a wide variety of leukocytes and only transiently reduce malignant cells in blood. Based on this study, THC/CBD shows no therapeutic potential for indolent B cell lymphomas (EudraCT trial no. 2014-005553-39).
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje